One of the biggest names in cannabis research and development, Cannabis Science, Inc is a biotech company that creates cannabinoid-based formulations for a variety of medical conditions. Among these are eight types of cancer, autism, attention deficit hyperactivity disorder (ADHD), and other neurobehavioral disorders.
The company has two major programs on cannabinoid medicines. One is on CS-TATI-1, targeted for patients with drug-resistant HIV strains. The development of this product particularly looks at an HIV-related cancer called Epidemic AIDS-Related Kaposi Sarcoma. Meanwhile, the other program is on CS-S/BCC-1, producing cannabinoid-based extracts that can be applied topically on skin cancer lesions. The company has seen some success in patients who have self-administered this treatment, and is now discussing it with FDA specialists.
Aside from its scientific programs and innovations, Cannabis Science also produces online videos promoting education on medical marijuana. It has also been a partner of various key players in the marijuana industry, including the medical cannabis consulting firm Michigan Green Technologies and the medical dispensing solutions company Medbox.
Cannabis Science was founded in 2000 as National Healthcare Technology. In 2009, it was reestablished as Cannabis Science and then went into public trading, with a new drive to advance its research on the pharmaceutical potential of marijuana. The company’s present CEO is Dorothy H. Bray, PhD, who was formerly the Global Director of HIV Research at GlaxoSmithKline. Other Cannabis Science executives include Chad S. Johnson as COO, Robert Kane as CFO, and Richard Ogden, PhD as Chief Scientific Officer.
Based in Cannabis Science is being traded in the OTC market as CBIS and is valued at USD 61.64 M. It is listed under the Medical Laboratories & Research industry, in the Healthcare sector.
Cannabis Science, Inc
6946 North Academy Boulevard
Suite B #254
Colorado Springs, CO 80918
Phone: +1 (888) 889-0888
Fax: +1 (866) 943-5085
Yahoo! Finance: CBIS News
Latest Financial News for CBIS
A new collaborative institute aims to study cannabis as part of its mission to increase access to evidence-based plant medicine in poor and developing nations. The International Phytomedicines Institute (IPI) at Harvard Medical School, was launched on May 26 during the 2019 Global Health Catalyst summit at Harvard Medical School, an annual conference focused primarily on reducing disparities to access to healthcare.
IRVINE, CA, July 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that Mr. Raymond C. Dabney (RCD), Founder and CEO of Cannabis Science, Inc. (CBIS), is completing a negotiated majority control acquisition of another U.S. public company.
To look at Cannabis One Holdings Inc. is to view a bloodied stock chart squashed by investors who took a sumo-wrestler like short position aiming break the company.
IRVINE, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce the appointment of Dr. Sulma Mohammed, Professor of Cancer Biology at Purdue University, to the Company’s Scientific Advisory Board. Dr. Mohammed has extensive knowledge of molecular biology, cell biology, biochemistry, and microbiology, basic and applied medical sciences through her graduate programs at Cornell University and Purdue University, as well as experience in cancer research from the basic levels, to pre-clinical research in animal models, through to human clinical trials.
IRVINE, CA, May 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the research and development of cannabinoid-based medicines, is proud to announce it has been introduced as one of the key industry partners in the recently launched, ground-breaking International Phytomedicines Institute (IPI) at Harvard Medical School. The International Phytomedicines Institute (IPI), launched during this year’s Harvard GHC Summit, is a transformative initiative by the Global Health Catalyst designed to elevate phytomedicines in global health, accelerate clinical translation and commercialization of evidence-based plant medicines/healthcare products and provide a world class core facility for research, and consultation on medicinal plants.